(Q38010773)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Treatment options for alopecia: an update, looking to the future (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Mariya Miteva

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

17 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

1271-1281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men.

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Finasteride treatment of hair loss in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Finasteride treatment of female pattern hair loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Comparative efficacy of various treatment regimens for androgenetic alopecia in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Enhanced Effect of Platelet-Rich Plasma Containing a New Carrier on Hair Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Lymphocytes, neuropeptides, and genes involved in alopecia areata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Guidelines for the management of alopecia areata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

21 January 2018

Alopecia areata update

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Alopecia areata: a new treatment plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata--a large retrospective study on 142 patients with a self-controlled design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Diphenylcyclopropenone immunotherapy in ophiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Extensive alopecia areata: not necessarily recalcitrant to therapy!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

308-nm excimer laser for the treatment of alopecia areata in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Systemic treatment for alopecia areata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Pulse corticosteroid therapy for alopecia areata: study of 139 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Prognostic factors in methylprednisolone pulse therapy for alopecia areata.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Serum levels of IL-18 and sIL-2R in patients with alopecia areata receiving combined therapy with oral cyclosporine and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Genome-wide association study in alopecia areata implicates both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Treatment of alopecia areata: "What is new on the horizon?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

The pathogenesis of primary cicatricial alopecias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Expression of hair follicle stem cells detected by cytokeratin 15 stain: implications for pathogenesis of the scarring process in cutaneous lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Insights from the asebia mouse: a molecular sebaceous gland defect leading to cicatricial alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Management of primary cicatricial alopecias: options for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Lichen planopilaris: report of 30 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Efficacy and safety of mycophenolate mofetil for lichen planopilaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Frontal fibrosing alopecia: a survey in 16 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Frontal fibrosing alopecia in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Cicatricial alopecia: discoid lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Thalidomide: dermatological indications, mechanisms of action and side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Treatment strategies for alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Alopecia areata: a long term follow-up study of 191 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

Low-Dose Excimer 308-nm Laser for Treatment of Lichen Planopilaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685160

10.1517/14656566.2012.685160

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22594679%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference